Thank you for this, very helpful.
Also, add a few other factors to the delay. Vitana X finalized the merger in November I believe. Prior to this GHHC was delinquent in their filings, so control had to be transferred to VITX, old financials from GHHC have to be collected and reviewed for submission, as well as all of VITX. All of this during COVID, all the while killing it in sales. For a newly merged European company just becoming familiar with the OTC landscape, they are doing just fine. Glad they focused on getting the business solid and sound instead of rushing the administrative side to make a few people satisfied. I'm growing impatient as well, but at least there are a massive amount of positives to ease my mind.